HCB301 for Hodgkin's Lymphoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called HCB301 for people with advanced solid tumors or Hodgkin's lymphoma that has returned or does not respond to standard treatments. Researchers aim to find the right dose and identify any side effects. Different groups will receive varying doses of HCB301 to determine the most effective one. This trial may suit those who have tried at least two other treatments for Hodgkin's lymphoma without success or have advanced solid tumors with no other treatment options. Participants must have a measurable tumor and be able to provide a sample of their tumor tissue. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Will I have to stop taking my current medications?
The trial does not specify if you must stop all current medications, but you cannot use certain cancer therapies, vitamin K antagonists like warfarin, or herbal medications before starting the trial. Some medications like low molecular weight heparin may be allowed on a case-by-case basis.
Is there any evidence suggesting that HCB301 is likely to be safe for humans?
Research shows that HCB301 may help slow the growth of cancer cells. Although detailed safety information for Hodgkin's Lymphoma is not yet available, other studies suggest that the treatment might be well-tolerated. In one previous study, patients did not experience infections or require blood transfusions.
Please note, this trial is in its early stages. Researchers are closely monitoring for any side effects and assessing how well participants tolerate the treatment.12345Why do researchers think this study treatment might be promising?
Researchers are excited about HCB301 for Hodgkin's Lymphoma because it offers a fresh approach compared to existing treatments like chemotherapy and radiation. HCB301 is unique because it targets specific proteins in cancer cells, potentially offering a more precise attack on the tumor with fewer side effects. Additionally, HCB301 is being tested in various dosages, from 0.3 mg/kg to 15.0 mg/kg, allowing researchers to fine-tune its effectiveness and optimize safety. This level of customization and targeted therapy could pave the way for more personalized cancer treatment options.
What evidence suggests that HCB301 could be an effective treatment for Hodgkin's Lymphoma?
Research is investigating HCB301 as a potential treatment for advanced cancers, such as Hodgkin's lymphoma. Early results suggest that HCB301, a type of protein, targets specific molecules that aid cancer growth. This action may enhance the immune system's ability to recognize and combat cancer cells. Although detailed information from human studies remains limited, early lab results appear promising. Ongoing studies, including this trial with various dosage arms, aim to confirm its effectiveness and safety for people.12678
Are You a Good Fit for This Trial?
This trial is for adults over 18 with advanced solid tumors or relapsed/refractory classical Hodgkin lymphoma. Participants must have measurable disease, be in good physical condition (ECOG 0-1), provide tissue samples, and have a life expectancy of at least 12 weeks. It's not suitable for those who still have standard treatment options that could work.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive HCB301 at escalating doses to evaluate safety, tolerability, and pharmacokinetics
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- HCB301
Find a Clinic Near You
Who Is Running the Clinical Trial?
FBD Biologics Limited
Lead Sponsor